<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="6052">
  <stage>Registered</stage>
  <submitdate>14/04/2016</submitdate>
  <approvaldate>14/04/2016</approvaldate>
  <nctid>NCT02742519</nctid>
  <trial_identification>
    <studytitle>A Study to Evaluate Efficacy and Safety of Ivacaftor in Subjects With Cystic Fibrosis Aged 3 Through 5 Years Who Have a Specified CFTR Gating Mutation</studytitle>
    <scientifictitle>A Phase 3b, 2-part, Randomized, Double-blind, Placebo-controlled Crossover Study With a Long-term Open-label Period to Investigate Ivacaftor in Subjects With Cystic Fibrosis Aged 3 Through 5 Years Who Have a Specified CFTR Gating Mutation</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>2015-001267-39</secondaryid>
    <secondaryid>VX15-770-123</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Cystic Fibrosis</healthcondition>
    <conditioncode>
      <conditioncode1>Inflammatory and Immune System</conditioncode1>
      <conditioncode2>Connective tissue diseases</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Inflammatory and Immune System</conditioncode1>
      <conditioncode2>Other inflammatory or immune system disorders</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Human Genetics and Inherited Disorders</conditioncode1>
      <conditioncode2>Cystic fibrosis</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Respiratory</conditioncode1>
      <conditioncode2>Other respiratory disorders / diseases</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Oral and Gastrointestinal</conditioncode1>
      <conditioncode2>Other diseases of the mouth, teeth, oesophagus, digestive system including liver and colon</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - ivacaftor
Treatment: drugs - Placebo

Experimental: Part 1-Sequence 1 - ivacaftor in Treatment Period 1 ?washout?placebo in Treatment Period 2

Experimental: Part 1 - Sequence 2 - placebo in Treatment Period 1?washout?ivacaftor in Treatment Period 2

Experimental: Part 2: ivacaftor - open label period


Treatment: drugs: ivacaftor


Treatment: drugs: Placebo


</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Part 1: Absolute change from baseline in LCI2.5 through 8 weeks of treatment</outcome>
      <timepoint>through 8 weeks</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Part 1: Absolute change from baseline in serum levels of immunoreactive trypsinogen at 8 weeks of treatment</outcome>
      <timepoint>at 8 Weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Part 1: Absolute change from baseline in fecal elastase-1 at 8 weeks of treatment</outcome>
      <timepoint>at 8 Weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Part 1: Absolute change from baseline in weight at 8 weeks of treatment</outcome>
      <timepoint>at 8 weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Absolute change from baseline in body mass index (BMI) at 8 weeks of treatment</outcome>
      <timepoint>at 8 weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Parts 1 and 2: Safety, as determined by number of subjects with adverse events (AEs) and serious adverse events (SAEs)</outcome>
      <timepoint>at Weeks 8, 48, 96, and 144</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Part 2: Absolute change from baseline in LCI2.5</outcome>
      <timepoint>at Weeks 48, 96, 144</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Par 2: Absolute change from baseline in CT scan</outcome>
      <timepoint>at Week 96</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Part 2: Absolute change from baseline in serum levels of immunoreactive trypsinogen</outcome>
      <timepoint>at Weeks 48, 96, and 144</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Part 2: Absolute change from baseline in fecal elastase-1</outcome>
      <timepoint>at Weeks 48, 96, and 144</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Part 2: Absolute change from baseline in weight-for-age z-score</outcome>
      <timepoint>at Weeks 48, 96, and 144</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Part 2: Absolute change from baseline in height-for-age z-score</outcome>
      <timepoint>at Weeks 48, 96, and 144</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Part 2: Absolute change from baseline in BMI-for-age z-score</outcome>
      <timepoint>at Weeks 48, 96, and 144</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Male or female with confirmed diagnosis of CF.

          -  Must have 1 of the following CFTR gating mutations on at least 1 allele: G551D, G178R,
             S549N, S549R, G551S, G1244E, S1251N, S1255P, or G1349D.

          -  Hematology, serum chemistry, and coagulation at Screening with no clinically
             significant abnormalities or concomitant diagnosis that would interfere with the LCI
             and CT scan study assessments, as judged by the investigator.</inclusivecriteria>
    <inclusiveminage>3</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>5</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  An acute upper or lower respiratory infection, pulmonary exacerbation, or changes in
             therapy (including antibiotics) for pulmonary disease within 4 weeks before Day 1

          -  Any clinically significant laboratory abnormalities at the Screening Visit that would
             interfere with the study assessments or pose an undue risk for the subject (in the
             opinion of the investigator)

          -  Abnormal liver function, at Screening, defined as =3 Ã— upper limit of normal (ULN), of
             any 3 or more of the following: serum aspartate transaminase (AST), serum alanine
             transaminase (ALT), gamma-glutamyl transpeptidase (GGT), serum alkaline phosphatase
             (ALP), and total bilirubin

          -  History of solid organ or hematological transplantation

          -  Any clinically significant "non-CF-related" illness within 2 weeks before Day 1

          -  Use of any moderate or strong inducers or inhibitors of cytochrome P450 (CYP) 3A
             within 2 weeks before Day 1

          -  Participation in a clinical study involving administration of either an
             investigational or a marketed drug within 30 days or 5 terminal half-lives (whichever
             is longer or as determined by the local requirements) before Screening</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Crossover</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1>The people receiving the treatment/s</masking1>
    <masking2 />
    <masking3 />
    <masking4>The people analysing the results/data</masking4>
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 3</phase>
    <anticipatedstartdate />
    <actualstartdate>1/05/2016</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>14</actualsamplesize>
    <recruitmentstatus>Terminated</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>1/08/2017</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>VIC</recruitmentstate>
    <hospital> - Parkville</hospital>
    <hospital> - South Brisbane</hospital>
    <hospital> - Subiaco</hospital>
    <hospital> - Westmead</hospital>
    <postcode> - Parkville</postcode>
    <postcode> - South Brisbane</postcode>
    <postcode> - Subiaco</postcode>
    <postcode> - Westmead</postcode>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Ontario</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>London</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Vertex Pharmaceuticals Incorporated</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>To evaluate the efficacy of ivacaftor treatment, as measured by lung clearance index (LCI),
      in subjects with cystic fibrosis (CF) who have a specified CF transmembrane conductance
      regulator (CFTR) gating mutation</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT02742519</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>